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Abstract
Background: Fat infiltration of the liver, muscle and pancreas is associated with insulin resistance and risk of diabetes.
Weight loss reduces ectopic fat deposition and risk of diabetes, but is difficult to sustain to due to compensatory
increases in appetite. Fermentable carbohydrates have been shown to decrease appetite and food intake, and
promote weight loss in overweight subjects. In animal studies, fermentable carbohydrate reduces ectopic fat
independent of weight loss. We aimed to investigate the effect of the fermentable carbohydrate inulin on weight
maintenance, appetite and ectopic fat in subjects with prediabetes.
Methods: Forty-four subjects with prediabetes were randomized to 18 weeks’ inulin or cellulose supplementation.
During weeks 1–9 (weight loss phase) all subjects had four visits with a dietitian to guide them towards a 5 % weight
loss. During weeks 10–18 (weight maintenance phase) subjects continued taking their assigned supplementation and
were asked to maintain the weight they had lost but were offered no further support. All subjects attended study
sessions at baseline, 9 and 18 weeks for measurement of weight; assessment of adipose tissue and ectopic fat content
by magnetic resonance imaging and magnetic resonance spectroscopy; glucose, insulin and GLP-1 levels following a
meal tolerance test; and appetite by ad libitum meal test and visual analogue scales.
Results: Both groups lost approximately 5 % of their body weight by week nine (−5.3 ± 0.1 % vs −4.3 ± 0.4 %, p = 0.13,
but the inulin group lost significantly more weight between 9 and 18 weeks (−2.3 ± 0.5 % vs −0.6 ± 0.4 %, p = 0.012).
Subjects taking inulin had lower hepatic (p = 0.02) and soleus muscle (p < 0.05) fat content at 18 weeks compared to
control even after controlling for weight loss and consumed less at the ad libitum meal test (p = 0.027). Fasting glucose
significantly decreased at week nine only (p = 0.005), insulin concentrations did not change, and there was a significant
increase in GLP-1 in the cellulose group at 9 and 18 weeks (p < 0.03, p < 0.00001).
Conclusion: Inulin may have a two-pronged effect on the risk of diabetes by 1) promoting weight loss 2) reducing
intrahepatocellular and intramyocellular lipid in people with prediabetes independent of weight loss.
Trial registration: Clinical trial number: NCT01841073.
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Background
Lifestyle interventions can significantly reduce the risk
of developing type 2 diabetes (T2DM) [1] with weight
loss being the primary mediator of the reduction in risk
[2]. However, outside of a labour-intensive clinical trial
setting, long-term weight loss is notoriously difficult to
achieve [3, 4].
One explanation for the rarity of successful weight loss
maintenance is that an energy deficit and loss of body
fat are both associated with increases in appetite and food
intake [5, 6]. Therefore, interventions such as glucagon-
like peptide-1 (GLP-1) agonists aimed at decreasing or
ameliorating such changes in appetite help promote long-
term weight loss maintenance [7]. Non-digestible carbo-
hydrate (dietary fibre) has long been linked to reduced
food intake [8], and fermentable carbohydrates (FCHO)
may be particularly effective [8]. This class of carbohydrate
passes undigested and unabsorbed from the upper
gastrointestinal tract to the colon where bacterial fer-
mentation produces short chain fatty acids (SCFA)
that can stimulate GLP-1, and regulate other appetite
hormones [9]. Furthermore, as a natural dietary com-
pound, FCHOs could represent a widely applicable
public health intervention. By promoting a natural re-
duction in appetite, less frequent clinical support may
needed. In a year-long study in overweight adoles-
cents, there was a significantly lower rise in body
mass index (BMI) in the inulin group, without receiv-
ing input from health professionals [10].
A key mediator of the beneficial effect of weight loss on
insulin sensitivity is the loss of ectopic fat [11], which is
highly correlated to insulin resistance and T2DM [11–13].
Intriguingly, FCHO has been shown to reduce ectopic fat
in animal studies independent of weight loss [14]. This
raises the possibility that this natural dietary carbohydrate
may not only enhance weight loss efforts, but may also
promote loss of this metabolically-deleterious fat in
humans, even after accounting for weight loss. In healthy
and insulin-resistant subjects, FCHO has been shown to
improve insulin sensitivity [15, 16], but it is not clear
whether a reduction in ectopic fat plays a role. No previ-
ous study has examined the effect of a dietary intervention
on ectopic fat in subjects with prediabetes.
Here we report the effect of 30 g/day (following a
4-week dose escalation period) inulin supplementation
taken alongside a 9-week weight loss program and a
9-week weight maintenance period. We hypothesise
the inulin will result in greater weight loss main-
tenance at the 18-week follow-up in subjects with
prediabetes, and will promote a reduction in ectopic
fat and insulin resistance independent of weight loss
assessed by using the gold-standard magnetic reson-
ance imaging (MRI) and magnetic resonance spectros-
copy (MRS) techniques.
Volunteers
Subjects with known prediabetes or high risk factors for
prediabetes were identified from local GPs registers.
Informed consent was obtained prior to the study. The
protocols were approved by the North West 1 Research
Ethics Committee (registration number: 10/H0717/32)
(Clinical trial number: NCT01841073) and conformed to
the Declaration of Helsinki. An oral glucose tolerance
test (OGTT) was performed to clarify glycaemic status
[17]. Inclusion criteria were age ≥ 18 years, BMI of
25–35 kg/m2, prediabetes (impaired fasting glucose
(IFG) and/or impaired glucose tolerance (IGT)) using
the American Diabetes Association criteria [17] and a
stable body weight for 3 months prior to the study. Exclu-
sion criteria were normal glucose tolerance, T2DM,
gastrointestinal disorders, pregnancy or breastfeeding,
prescribed medication that affects appetite or glucose
homeostasis and consumption of prebiotic products or
antibiotic use within 3 months of the study start date.
Volunteers were randomised by BMI and gender using a
random-number table, with an allocation ratio of 1:1.
Experimental design
The study was a double-blinded randomized parallel
control trial examining the effect of 30 g/day inulin
(Synergy1,Orafti, Tienen, Belgium) versus the control
cellulose (Vitacel® Powdered Cellulose L 600–20, J.
Rettenmaier & Söhne GmbH + Co.) alongside a 9-week
weight loss and 9-week weight maintenance program
(Fig. 1). The fibre cellulose was chosen as a comparator
as this unbranched polymer of glucose molecules linked
by (β4-1) bonds undergoes minimal colonic fermenta-
tion. The 30 g dose was chosen based on previous stud-
ies by our group [18, 19]. Both supplements were given
as 10 g sachets taken three times a day with food or
drink. To reduce potential gastrointestinal side-effects
supplements were increased by 10 g/day every 2 weeks
to reach the 30 g/day dose. Therefore, by week five of the
nine-week weight loss phase, all subjects were on the
maximum 30 g/day dose. The inulin and cellulose sachets
were assigned letter A or B and were otherwise identical.
During the 9-week weight loss program each subject
underwent a standardized dietary intervention comprising
four dietary sessions 2–3 weeks apart with a registered
dietitian (Fig. 1). The dietitian was blinded to the sup-
plement allocation. Energy requirements and assigned
portion sizes for starches, protein, milk and dairy, fats and
sugars and fruits and vegetables were determined using a
ready-reckoner developed at Hammersmith Hospital.
Following the 9-week visit, subjects were given no further
input or support from the study team. They were merely
asked to try and maintain the weight that they had lost.
All subjects attended a study day at baseline, 9 weeks
(representing the end of the weight loss phase) and
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18 weeks (end of weight maintenance phase) for a meal
tolerance test (MTT) (Ensure Plus™ (220 ml), Total
energy: 1380 kJ, 44.4 g carbohydrate, 10.8 g fat, 13.8 g
protein). Blood samples were taken at −15, 0, 5, 10, 15,
20, 30, 45, 60, 90, 120, 150, 180 min for measurement of
glucose, insulin and GLP-1 (Fig. 1).
Appetite was assessed during the MTT using validated
[20] visual analogue scales (VAS) at frequent intervals,
followed by an ad libitum meal test [20]. The appetite
questions used were “How hungry are you right now?”
(general hunger), “How much do you think you could
eat right now?” (prospective food consumption), “How
pleasant would it be to eat right now?” (desire to eat)
and “How full do you feel right now?” (feeling of fullness
in the stomach) (Additional file 1).
Body composition was assessed by a 9-electrode
bioelectrical impedance (BIA) device (Tanita BC-418
MA Segmental Body Composition Analyzer) (Tanita
Corporation, Tokyo, Japan). The BIA device provides
estimates of % body fat (±0.1 %), fat mass (±0.1 kg), and
free fat mass (±0.1 kg). In addition, a subset of subjects
who were eligible (no metal in situ or reported claus-
trophobia) (n = 20) underwent MRI and MRS to
assess total and regional fat volumes at baseline, week
nine and week 18. Rapid T1-weighted magnetic
resonance images were obtained using a 1.5 T Phillips
Achiva scanner (Phillips, Best, the Netherlands) [21]
with intrahepatocellular lipid (IHCL), and intram-
yocellular lipid in the soleus and tibilalis muscles
(IMCL-S and IMCL-T, respectively) assessed by MRS
as previously described [22].
Compliance was assessed by asking subjects to return
unused sachets and breath hydrogen was measured as a
proxy of colonic fermentation using a breath hydrogen
monitor (Gastrolyzer, Bedfont Scientific Ltd. Kent, UK).
Laboratory analysis
Glucose was collected into fluoride oxalate tubes and
measured using an Architect ci8200 analyzer (Abbott
Diagnostics, Maidenhead, UK), with an assay detection
limit of 0.3 mmol/L and an intra-assay coefficient of
variation (CV) of 1 %. Plasma insulin samples were
collected into serum gel separator tubes containing gel
clotting activator Vacutte® and measured with a com-
mercial radioimmunoassay kit (Millipore; Watford, UK).
The sensitivity and intra-assay CV for insulin were 7.1
pmol, and 3.0 % respectively. GLP-1 samples were
collected into lithium heparin tubes, with aprotinin
(Trasylol, Bayer, Newbury, UK) (200 μL/7.5 ml blood)
added. Blood samples were spun at 4000 g at 4 °C for 10
mins, separated into plasma and stored at −20 °C until
analysed using an in-house radioimmunoassay [23]. The
sensitivity and intra-assay CV of the GLP-1 assay were
7.5 pmol/l and 3.3 % respectively.
Calculations and statistical analysis
Based on a study by Parnell et al. [24] with an expected
weight loss of 2.0 kg and a standard deviation of 2.0 kg
Fig. 1 Schematic showing study outline, including the timings of blood samples, VAS and breath hydrogen measure during the MTT. H2: breath
hydrogen measure; MTT: meal tolerance test; MRS: magnetic resonance imaging; MRS: magnetic resonance spectroscopy; VAS: visual analogue scales
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based on 0.8 power to detect a significant difference
(P < 0.05, 2-sided) we estimated a minimum of 32
subjects were needed; 16 additional subjects were added
to account for dropouts. Data are presented as mean ±
standard error of the mean (SEM) for normally distributed
data and median and interquartile range for non-normally
distributed variables. The postprandial response curves for
GLP-1, glucose and insulin were calculated as total area
under the curve (tAUC) using the trapezoid rule. The pri-
mary outcome of weight change between the inulin and
cellulose groups was calculated using an ANCOVA with
baseline weight as a covariate. The delta change between
the insulin and cellulose groups (between group differ-
ence) for glucose, inulin, GLP-1, and measures of adipos-
ity and ectopic fat were compared using ANCOVAs, with
change in weight as a covariate. Non-parametric tests
were used for variables not normally distributed. A p value
of less than 0.05 was considered significant. Analyses were
performed using GraphPad Prism Version 5.0 (GraphPad
Software, San Diego, CA) and ANCOVA was performed
using SPSS 20.0 (SPSS Inc. Chicago, IL USA). The homeo-
static model assessment of insulin resistance (HOMA-IR)
and Matsuda index were used to measure fasting and
postprandial insulin sensitivity [25, 26].
Results
Subject characteristics
The baseline characteristics of the subjects are shown in
Table 1. There were no differences between the inulin
and cellulose groups in any of the baseline characteristics.
A total of 44 subjects were recruited and randomised of
whom five withdrew from the study before week nine,
including one taking inulin and one taking cellulose who
dropped out due to side-effects. An additional subject
withdrew following the week nine visit. See CONSORT
diagram (Additional file 1). Furthermore, due to a drop-
out (n = 1) scheduling difficulties (n = 2), withdrawal of
consent for MRI (n = 1) and no longer being eligible for
MRI (n = 1) five subjects who underwent baseline and
week nine MRI scans did not have a scan at 18 weeks.
Therefore 19 subjects completed a follow-up MRI at
9-weeks (inulin group: three females and seven males;
cellulose group: four females and five males), and 14
subjects completed a follow-up MRI at 18 weeks in-
sulin group: three females, six males; cellulose group:
three females and two males).
Compliance
On average, ten out of 189 sachets (5 %) were returned
at week 18. The breath hydrogen levels increased by
15.0 ± 6.3 ppm (n = 20) in the inulin group vs 2.3 ±
1.6 ppm (n = 19) in the cellulose group at week nine
(p = 0.07), a difference which reached significance at
week 18 (14.8 ± 3.7 ppm, n = 20 vs 0.19 ± 0.8 ppm, n = 18,
p < 0.001).
Anthropological outcomes
Weight
As intended by the study design, both groups lost similar
amounts of weight during the weight loss phase (−5.3 ±
0.1 %, n = 20 vs −4.3 ± 0.4 %, n = 19, p = 0.13). Measured
as absolute weight loss: −4.6 kg ± 0.6 kg vs −3.61 ±
0.3 kg. However, during the weight maintenance phase
(weeks 9–18), the inulin group lost significantly more
weight compared to the control (−2.3 ± 0.5 %, n = 20
vs −0.6 ± 0.4 %, n = 18, p = 0.012). Measured as absolute
weight loss: −1.8 ± 0.4 kg vs −0.5 ± 0.3 kg (Fig. 2).
Body composition
Body fat percent as analysed by BIA at week 9 and
18 showed a greater reduction in the inulin group
compared to the cellulose group (−2.8 ± 0.4 %, n = 20
vs −1.2 ± 0.4 %, n = 19, p < 0.01) and (−3.7 ± 0.6 %, n = 20
vs −1.1 ± 0.6 %, n = 18, p = 0.01) respectively (Fig. 2). In
the sub-group of subjects who underwent MRI, the
percentage body fat measurements at 9-weeks
showed a similar trend towards a reduction in body
fat (−1.7 ± 0.6 %, n = 10 vs −0.1 ± 0.6 %, n = 9, p = 0.08) al-
though this did not reach statistical significance. The
delta change was not different at 18 weeks (−2.4 ±
1.2 %, n = 9 vs −2.2 ± 3.1 %, n = 5, p = 0.93). The delta
change in other fat depots was not different at 9 or
18 weeks (Additional file 1).
Intrahepato- and intramyocellular lipid
Intrahepatocellular lipid was reduced in the inulin
group, and the delta change was significant when com-
pared to the cellulose group at 9 and 18 weeks even after
controlling for weight loss (9 weeks: −9.6 ± 2.8 %, n = 10
Table 1 Subject characteristics for each arm of the study
Inulin (n = 20) Cellulose (n = 19) p value
Gender (M:F) 13:8 11:9 0.66
Age (years) 58.2 ± 12.0 59.7 ± 8.9 0.53
Weight (kg)b 88.2 ± 14.0 83.4 ± 19.7 0.28
BMI (kg/m2) 30.8 ± 4.1 30.0 ± 2.3 0.41
FPG (mmol/L) 5.7 ± 0.5 5.9 ± 0.6 0.20
2hPG (mmol/L) 7.3 ± 2.3 7.3 ± 2.0 0.99
HbA1c (%) and
(mmol/mola)
5.9 ± 0.1 (41.3 ± 1.4) 5.7 ± 0.1 (38.8 ± 0.9) 0.78
Fasting insulin
(pmol/L)
95.4 (116.8)b 114.1 (132.9)b 0.17
Values are means and SD. Gender is expressed as a ratio of males to females.
There were no significant differences between the groups for any of the
baseline variables. FPG fasting plasma glucose; 2hPG 2-hour plasma glucose
aSI units for HbA1c shown in brackets
bFasting insulin was not normally distributed so values given are for median
(interquartile range)
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vs −0.5 ± 2.7 %, n = 9, p < 0.04); (18 weeks: −10.0 ±
2.6 %, n = 9 vs −2.3 ± 2.5 %, n = 5, p = 0.02) (Fig. 3). The
fat content of the soleus muscle was also significantly re-
duced at 9 and 18 weeks (9 weeks: −0.7 ± 0.3 %, n = 10
vs 0.8 ± 0.3 %, n = 9, p < 0.005); (18 weeks: −1.3 ± 1.4 %,
n = 9 vs 4.8 ± 3.0 %, n = 5, p < 0.05) (Fig. 4) but not the
tibialis muscle (9 weeks: −1.4 ± 1.0 % n = 10 vs −1.0 ±
1.4 %, n = 9, p = 0.82); (18 weeks: −2.2 ± 0.8 %, n = 9 vs
−2.5 ± 2.7 %, n = 5, p = 0.93).
Measures of appetite
Visual analogue scales
Subjective appetite assessment showed no differences in
tAUC hunger, desire to eat, or fullness at 9 and 18 weeks
between the inulin and cellulose groups (Additional file 1).
There was no difference in tAUC for the question “How
much do you think you could eat right now?” (prospective
food consumption) at week nine (−62.9 ± 58.2, n = 20
vs −117.8 ± 44.2, n = 19, p = 0.46) but subjects in the
cellulose reported significantly greater tAUC for the
prospective food consumption question than the inu-
lin group at week 18 (4.5 ± 37.9, n = 20 vs 774.5 ±
86.97, n = 18) p = <0.0001).
Food intake from Ad Libitum meal
Subjects in the inulin group ate significantly less than
the cellulose group at week nine compared to the baseline
visit (−127.0 ± 45.4 g, n = 20 vs −0.47 ± 22.5 g, n = 19,
Fig. 2 Percentage weight loss and body fat loss measured by BIA at week nine and week 18 in inulin and cellulose groups. Analysis was done
by ANCOVA with baseline weight as a covariate. Weight loss at week nine was not significantly different between inulin and cellulose groups
(−5.3 ± 0.1 %, n = 20 vs −4.3 ± 0.4 %, n = 19, p = 0.13). Between weeks 9–18 the inulin group lost significantly more than the cellulose group
(−2.3 ± 0.5 %, n = 20 vs −0.6 ± 0.4 %, n = 18, p = 0.012). Analysis for body loss was done by ANCOVA with baseline weight as a covariate. The
inulin group lost a greater percentage of body fat as measured by BIA at 9 (−2.8 ± 0.4 %, n = 20 vs −1.2 ± 0.4 %, n = 19, p < 0.01) and 18 weeks
(−3.7 ± 0.6 %, n = 20 vs −1.1 ± 0.6 %, n = 18, p = 0.01). ANCOVA: analysis of covariance; BIA: bioelectrical impedance
Fig. 3 Change in intrahepatocellular lipid (IHCL) at weeks 9 and 18
in inulin and cellulose groups. Analysis was done by ANCOVA with
change in body weight as a covariate. IHCL was significantly
reduced in subjects randomised to the inulin supplement
compared to the cellulose at 9 (−9.6 ± 2.8 %, n = 10 vs −0.5 ±
2.7 %, n = 9, p < 0.04) and 18 weeks (−10.0 ± 2.6 %, n = 9 vs −2.3 ±
2.5 %, n = 5, p = 0.02). ANCOVA: analysis of covariance; IHCL:
intrahepatocellular lipid
Fig. 4 Change in intramyocellular lipid in the soleus muscle (IMCL-S)
at weeks 9 and 18 in inulin and cellulose groups. Analysis was done
by ANCOVA with change in body weight as a covariate. IMCL-S was
significantly reduced at 9 and 18 weeks in the inulin group compared to
cellulose: (9 weeks: −0.7 ± 0.3 %, n= 10 vs 0.8 ± 0.3 %, n= 9, p< 0.005);
(18 weeks: −1.3 ± 1.4 %, n= 9 vs 4.8 ± 3.0 %, n= 5, p< 0.05). ANCOVA:
analysis of covariance; IHCL: intrahepatocellular lipid
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p = 0.027). There were no differences in food intake
between baseline and week 18 between the inulin and
cellulose groups (−87.3 ± 51.3 g, n = 20, vs −1.2 ±
23.7 g, n = 18, p = 0.18) (Additional file 1).
Biochemical outcomes
Glucose
There was a significant reduction in fasting plasma
glucose (FPG) in the inulin group compared to con-
trol at week nine (−0.23 ± 0.17 mmol/L, n = 20 vs
0.44 ± 0.24 mmol/L, n = 19, p = 0.005) after controlling
for weight loss but the change at week 18 was no
longer significant (−0.40 ± 0.19 mmol/L, n = 20 vs
0.16 ± 0.23 mmol/L, n = 18, p = 0.08) (Fig. 5i and ii).
Although glucose tAUC decreased in both groups,
there was no between group difference at week nine
(p = 0.37) or at week 18 (p = 0.37) once controlled for
weight loss (Fig. 5iii).
Insulin
As expected following weight loss, the insulin tAUC de-
creased in both inulin and cellulose groups (Fig. 6i and ii),
but there were no between-group differences at week nine
(p = 0.66) or week 18 (p = 0.27). The delta change in
fasting insulin was also similar between inulin and cellu-
lose at week nine (−23.3 ± 15.4 pmol/L, n = 18 vs −30.5 ±
17.6 pmol/L, n = 17, p = 0.82) and week 18 (−35.5 ± 17.8
pmol/L, n = 18 vs −14.7 ± 18.7 pmol/L, n = 17, p = 0.53).
Note, due to haemolysis it was not possible to analyse
all samples.
Insulin sensitivity
There were no differences in delta change of HOMA-IR at
week nine (−0.6 ± 0.3, n = 18 vs −0.4 ± 0.3, n = 17, p = 0.65)
and week 18 (−0.7 ± 0.3, n = 18 vs −0.2 ± 0.4, n = 17,
p = 0.23) or Matsuda Index at week nine (0.5 ± 0.5,
n = 17 vs 0.01 ± 0.2, n = 17, p = 0.56) or week 18 (0.4 ± 0.7
n = 17, vs 0.1 ± 0.3, n = 17, p = 0.75) between the inulin
and cellulose groups after adjusting for weight lost.
GLP-1
At 9 and 18 weeks the GLP-1 tAUC decreased following
inulin supplementation and increased in the cellulose
group and the delta changes between the groups were
significantly different (−1005 ± 457, n = 17 vs 614 ± 399,
n = 16, p < 0.03) and 18 weeks (−525 ± 315, n = 17 vs
4500 ± 710.4 n = 16, p < 0.0001), respectively.
Fig. 5 Time course data for plasma glucose at baseline, 9-weeks and 18 weeks for inulin (i) and cellulose supplementation (ii). Black line = baseline; dark
grey line = 9-week visit; light grey line = 18-week visit. tAUC was calculated using the trapezoid method. ANCOVA using weight change as a covariate
was used to analyse delta change between the inulin and cellulose groups. Glucose tAUC delta change at week nine(135 ± 134, n= 17 vs 87 ± 42, n= 17,
p= 0.37) or at week 18 (−267 ± 104, n= 17 vs −38 ± 21, n= 17, p = 0.37) did not differ between groups once controlled for weight loss. There was a
significant difference in the FPG delta change between groups at week nine once controlled for weight loss (−0.23 ± 0.17 mmol/L, n= 20 vs 0.44 ±
0.24 mmol/L, n= 19, p = 0.005) while the change at week 18 was no longer significant (−0.40 ± 0.19 mmol/L, n= 20 vs 0.16 ± 0.23 mmol/L, n= 18,
p= 0.08) (iii). ANCOVA: analysis of covariance; FPG; fasting plasma glucose; tAUC: total area under the curve
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Discussion
Weight loss reduces the risk of diabetes, and medications
which reduce appetite can promote long-term weight loss
[7]. Previous studies have shown that FCHO reduces
appetite, food intake and body weight, independent of
lifestyle change [10, 18, 24]. We extend these findings to
show that the consumption of inulin enhances a trad-
itional calorie-restricted lifestyle program. An added bene-
fit of the inulin supplement was a greater reduction in
intrahepatocellular and intramyocellular lipid in the soleus
muscle even after accounting for weight lost.
Expert bodies recognize the importance of frequent
visits in primary care (more than once a month, face-to-
face contact during the first three months) in achieving
long-term weight loss maintenance [27]. However, the
labour-intensive nature of this approach reduces its
widespread applicability. Therefore an important compo-
nent of our study design was to ensure that the subjects
would not receive dietary advice or support during the
final 2 months of the study. Our finding that the inulin
group lost more weight between weeks 9–18 compared
to cellulose therefore suggests that inulin may be a use-
ful adjunct to traditional lifestyle approaches to diabetes
prevention. Furthermore, despite the 5 % weight loss at
week nine, subjects taking inulin ate significantly less
(~270 kcal less, p = 0.027) at the follow-up ad libitum
meal, with no consequent rebound in food intake at the
18 week visit despite a total 7 % weight loss in the inulin
group, suggesting that inulin’s effect on weight manage-
ment is mediated via appetite modulation.
Unexpectedly, the cellulose group also continued to
lose weight during the weight maintenance period, albeit
a modest amount. Firstly, the length of the study was
likely not long-enough to measure true long-term weight
loss maintenance, and both groups may have simply
continued with the dietary changes they had made
during the 9-week weight loss period. Weight loss tends
to plateau at 6 months, after which weight exhibits a
gradual but continuous rise [28]. We had selected the
9-week weight loss and 9-week weight maintenance
periods as a balance between degree of participant
burden and feasibility [29, 30]. Our findings at this
time therefore support a role for inulin in weight loss,
as opposed to weight-loss maintenance. We suggest
that a longer follow-up period should be incorporated
in future study designs.
Secondly, we had selected cellulose as the control as it
is known to be the least fermentable of the fibres [31].
However, adaptations of the gut microbiota over time
have also been reported following cellulose ingestion
[32] and cereal fibre (24 g per day) has been shown to
increase GLP-1 secretion taken over a year [33]. We sug-
gest that more work should be carried out to understand
the physiochemical properties of dietary fibres and their
relationship to weight management. Nevertheless, since
dietary fibre is inversely associated with BMI [8, 34] the
use of cellulose as a control group would suggest our data
underestimate the likely magnitude of effect of inulin on
weight loss.
Inulin consumption not only promoted weight loss
but was also associated with greater loss of triglyceride
in the liver (IHCL) and soleus muscle (IMCL-S), even
after controlling for differences in weight lost. We were
able to collect MRI and MRS data on 19 subjects, and
similar studies examining, IHCL, IMCL and adiposity
have used comparable sample sizes [35, 36]. We there-
fore extend findings of a beneficial effect of FCHO on
ectopic fat from animal studies [14], and from human
studies in non-alcoholic fatty liver disease [37] to suggest
that FCHO is also able to reduce IHCL and IMCL-S
Fig. 6 Time course data for plasma insulin at baseline, 9 weeks and 18 weeks for inulin (i) and cellulose supplementation (ii). Black line = baseline;
dark grey line = 9-week visit; light grey line. tAUC was calculated using the trapezoid method. ANCOVA using weight change as a covariate was
used to analyse delta change between the inulin and cellulose groups. After controlling for weight lost the delta change in insulin tAUC
following inulin supplementation was similar to the cellulose group at week nine (−2366 ± 575, n = 17 vs −1566 ± 1724, n = 17, p = 0.66) and week 18
(−2643 ± 671, n = 17 vs −1264 ± 1045, n = 17, p = 0.27). The delta change in fasting insulin was also similar between inulin and cellulose at week nine
(−23.3 ± 15.4 pmol/L, n = 18 vs −30.5 ± 17.6 pmol/L, n = 17, p = 0.82) and week 18 (−35.5 ± 17.8 pmol/L, n = 18 vs −14.7 ± 18.7 pmol/L, n = 17, p = 0.53).
ANCOVA: analysis of covariance; tAUC: total area under the curve
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content in subjects at risk of diabetes independent of
weight loss. A previous study has shown that 12 weeks’
supplementation with the FCHO oligofructose led to
greater weight loss as fat as measured by x-ray absorpti-
ometry [24]. However, our data on the proportion of
weight lost as fat are inconclusive, given the lack of
significance in the MRI data and the caution required in
interpreting bioimpedance measurements.
The reduction in IHCL following inulin supplementa-
tion is of particular importance given the potent and
consistent relationship between triglyceride content of the
liver and metabolic disease, particularly diabetes [11, 13].
Furthermore, previous studies have found an increase in
lipid content of the soleus muscle but not the tibialis in
the off-spring of subjects with type II diabetes [12] and
Indian males with diabetes have significantly higher
IMCL-content in the soleus compared to healthy controls
[38]. The greater oxidative muscle fibre content of the
soleus muscle may be related to insulin resistance due to
altered insulin-dependent glucose transport [39].
The mechanism by which FCHO reduces fat deposition
appears to be related to increased fat oxidation. Rats fed a
diet high in viscous (fermentable) fibres have increased ex-
pression of carnitine palmitoyltransferase 1B (CPT-1B) –
the rate-limiting enzyme in the soleus muscle, alongside
other key fat oxidation genes: peroxisome proliferator-
activated receptors 1α and δ, uncoupling protein 3, and
citrate synthase [40]. In humans, fat oxidation is increased
3 h after consumption of a low glycaemic index breakfast,
indicating that fermentation of unavailable carbohydrates
may influence oxidation in vivo [41]. It has also recently
been shown that inulin down-regulates hepatic lipid pro-
duction alongside increases in portal SCFA concentrations
in mice fed a high-fat diet [42].
Despite the effect of inulin on liver fat we did not
observe any added effect on insulin sensitivity after
accounting for weight loss. Dietary studies on the effects
of FCHO on insulin sensitivity have shown improvements
in peripheral and/or hepatic insulin sensitivity [15, 16, 43].
We did not find any changes in fasting (HOMA-IR) or
postprandial insulin sensitivity (Matsuda Index) in this
study. However, the distinct pathophysiology which un-
derpins the different prediabetic states may have been a
confounding factor. Subjects with IFG are known to have
hepatic insulin resistance, but normal peripheral insulin
sensitivity [44]; while subjects with IGT are known to have
normal or mild hepatic, but marked peripheral insulin
resistance [44]. It is not known whether inulin affects
hepatic or peripheral insulin sensitivity, and this study was
not powered to examine differences between the predia-
betic states. This should be considered in future studies.
Nevertheless, there was a significant reduction in FPG
after controlling for weight loss in the inulin group at
week nine. It is unclear why this was no longer different at
week 18, but insoluble fibres have shown repeated inverse
associations with diabetes risk in cohort studies [45], with
the mechanism currently unknown. Potentially, the fer-
mentation of cellulose and the rise in GLP-1 may have
played a role. Furthermore, other changes made in the diet
in both the inulin and cellulose groups may also have
contributed, as all subjects were encouraged to eat five or
more servings of fruit and vegetables daily and increase
their consumption of high-fibre foods. Total dietary fibre
is known to be inversely related to a number of cardiovas-
cular risk factors [46]; however our data point to specific
metabolic effects of fermentable fibres which may be of
particular benefit to individuals at risk of diabetes. Use of
stool analysis in future studies would be very useful to
help delineate some of these effects.
We acknowledge some limitations in the study. While
compliance in dietary studies is always challenging, the
breath hydrogen significantly increased when the supple-
ment was being taken, providing a degree of dietary
compliance. The high return rate of the used sachets
also suggests that the effects seen in this study were due
to chronic consumption of the supplementation. We
also did not measure physical activity which is known to
affect insulin sensitivity and loss of ectopic fat. We
therefore cannot rule out that exercise may have influ-
enced the results seen here, and activity meters should
be used in future studies. Finally, there are known
gender differences in body composition [47]. While the
study did not aim to determine gender differences in the
study outcomes, this is certainly something that should
be examined in a study powered to do so.
Conclusion
In conclusion, our findings support a role for fermentable
fibres in modifying two key risk factors in diabetes devel-
opment: weight management and ectopic fat deposition.
Inulin, and possibly other fermentable carbohydrates,
could therefore represent a potentially effective interven-
tion at the population level.
Additional file
Additional file 1: Supplementary material. (DOCX 87 kb)
Abbreviations
ANCOVA: Analysis of covariance; BIA: Bioelectrical impedance; CPT-
1b: Carnitine palmitoyltransferase 1B; CV: Coefficient of variation;
FCHO: Fermentable carbohydrate; FPG: Fasting plasma glucose;
GLP-1: Glucagon-like peptide 1; HOMA-IR: Homeostasis model assessment
of insulin resistance; IFG: Impaired fasting glucose; IGT: Impaired glucose
tolerance; IHCL: Intrahepatocellular lipid; IMCL: Intramyocellular lipid;
MRI: Magnetic resonance imaging; MRS: Magnetic resonance spectroscopy;
MTT: Meal tolerance test; OGTT: Oral glucose tolerance test; SCFA: Short-chain
fatty acids; SEM: Standard error of the mean; tAUC: Total area under the curve;
T2DM: Type 2 diabetes; VAS: Visual analogue scales; VAT: Visceral adipose tissue;
2hPG: 2 h plasma glucose.
Guess et al. Nutrition & Metabolism  (2015) 12:36 Page 8 of 10
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NG, AD and GF designed the study. NG collected the data. NG, AD and GF
wrote the manuscript. NO reviewed/edited the manuscript. JB and ELT
collected and analysed the MRI data and reviewed the manuscript. All
authors read and approve the final manuscript.
Acknowledgements
Nicola Guess was funded by a Diabetes UK Allied Health Professional Fellowship.
The Section is also funded by grants from the MRC, BBSRC, NIHR, an Integrative
Mammalian Biology (IMB) Capacity Building Award, a FP7- HEALTH- 2009–241592
EuroCHIP grant and is supported by the NIHR Imperial Biomedical Research
Centre Funding Scheme. Gary Frost is funded by an NIHR Senior Investigator
award. This article presents independent research carried out at the NIHR/
Wellcome Trust Imperial Clinical Research Facility. The views expressed are those
of the authors and not necessarily those of the NHS, the NIHR or the
Department of Health. The authors would like to thank Giuliana Durighel, Julie
Fitzpatrick, Marina Quinlan and Catherine Holden with their assistance with the
MRI studies; and also Natarin Caengprasath for assistance with screening
participants and carrying out the research study days.
Author details
1Nutrition and Dietetic Research Group, Imperial College, London,
Hammersmith Hospital, London W12 0NN, UK. 2Division of Diabetes,
Endocrinology and Metabolism, Imperial College NHS Trust, London, UK.
3Department of Life Sciences, Faculty of Science and Technology, University
of Westminster, London W1W 6UW, UK. 4Division of Diabetes, Endocrinology
and Metabolism, 6th Floor Commonwealth Building, Faculty of Medicine,
Imperial College Hammersmith Campus, Du Cane Road, London W12 ONN,
UK.
Received: 1 September 2015 Accepted: 15 October 2015
References
1. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al.
The effect of metformin and intensive lifestyle intervention on the
metabolic syndrome: the Diabetes Prevention Program randomized trial.
Ann Intern Med. 2005;142:611–9.
2. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al.
Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes
Care. 2006;29(9):2102–7.
3. Whittemore R, Melkus G, Wagner J, Northrup V, Dziura J, Grey M. Translating
the diabetes prevention program to primary care: a pilot study. Nurs Res.
2009;58:2.
4. Diabetes Prevention Program (DPP) Research Group. The Diabetes
Prevention Program (DPP): description of lifestyle intervention. Diabetes
Care. 2002;25(12):2165–71.
5. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A,
et al. Long-term persistence of hormonal adaptations to weight loss.
N Eng J Med. 2011;365:1597–604.
6. Doucet E, Imbeault P, St-Pierre S, Alméras N, Mauriège P, Richard D, et al.
Appetite after weight loss by energy restriction and a low-fat diet-exercise
follow-up. Int J Obes Relat Metab Disord. 2000;24(7):906–14.
7. De Silva A, Bloom SR. Gut hormones and appetite control: a focus on PYY
and GLP-1 as therapeutic targets in obesity. Gut Liver. 2012;6(1):10–20.
8. Wanders AJ, van den Borne JJ, de Graaf C, Hulshof T, Jonathan MC,
Kristensen M, et al. Effects of dietary fibre on subjective appetite, energy
intake and body weight: a systematic review of randomized controlled
trials. Obes Rev. 2011;12(9):724–39.
9. Sleeth ML, Thompson EL, Ford HE, Zac-Varghese SE, Frost G. Free fatty acid
receptor 2 and nutrient sensing: a proposed role for fibre, fermentable
carbohydrates and short-chain fatty acids in appetite regulation. Nutr Res
Rev. 2010;23(1):135–45.
10. Abrams SA, Griffin IJ, Hawthorne KM, Ellis KJ. Effect of prebiotic supplementation
and calcium intake on body mass index. J Pediatr. 2007;151(3):293–8.
11. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R.
Reversal of type 2 diabetes: normalisation of beta cell function in
association with decreased pancreas and liver triacylglycerol. Diabetologia.
2011;54(10):2506–14.
12. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, et al.
Intramyocellular triglyceride content is a determinant of in vivo insulin
resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy
assessment in offspring of type 2 diabetic parents. Diabetes. 1999;48:1600–6.
13. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in type
2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin
resistance. Am J Physiol Endocrinol Metab. 2003;285:E906–16.
14. So PW, Yu WS, Kuo YT, Wasserfall C, Goldstone AP, Bell JD, et al. Impact of
resistant starch on body fat patterning and central appetite regulation.
PLoS ONE. 2007;2(12):e1309.
15. Robertson MD, Currie JM, Morgan LM, Jewell DP, Frayn KN. Prior short-term
consumption of resistant starch enhances postprandial insulin sensitivity in
healthy subjects. Diabetologia. 2003;46:659–65.
16. Robertson MD, Bickerton AS, Dennis AL, Vidal H, Frayn KN. Insulin-sensitizing
effects of dietary resistant starch and effects on skeletal muscle and adipose
tissue metabolism. Am J Clin Nutr. 2005;82:559–67.
17. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al.
Impaired fasting glucose and impaired glucose tolerance implications for
care. Diabetes Care. 2007;30:753–9.
18. Pedersen C, Lefevre S, Peters V, Patterson M, Ghatei MA, Morgan LM, et al.
Gut hormone release and appetite regulation in healthy non-obese
participants following oligofructose intake: a dose-escalation study.
Appetite. 2013;66:44–53.
19. Daud NM, Ismail NA, Thomas EL, Fitzpatrick JA, Bell JD, Swann JR, et al. The
impact of oligofructose on stimulation of gut hormones, appetite regulation
and adiposity. Obesity. 2014;22(6):1430–8.
20. Blundell J, de Graaf C, Hulshof T, Jebb S, Livingstone B, Lluch A, et al.
Appetite control: methodological aspects of the evaluation of foods. Obes
Rev. 2010;11:251–70.
21. Thomas EL, Saeed N, Hajnal JV, Brynes A, Goldstone AP, Frost G, et al. Magnetic
resonance imaging of total body fat. J Appl Physiol. 1998;85:1778–85.
22. Thomas EL, Hamilton G, Patel N, O’Dwyer R, Doré CJ, Goldin RD, et al.
Hepatic triglyceride content and its relation to body adiposity: a magnetic
resonance imaging and proton magnetic resonance spectroscopy study.
Gut. 2005;54:122–7.
23. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7–36: a
physiological incretin in man. Lancet. 1987;2:1300–4.
24. Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is
associated with decreased ghrelin and increased peptide YY in overweight
and obese adults. Am J Clin Nutr. 2009;89:1751–9.
25. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment
(HOMA) evaluation uses the computer program. Diabetes Care.
1998;21:2191–2.
26. Maki KC, McKenney JM, Farmer MV, Reeves MS, Dicklin MR. Indices of insulin
sensitivity and secretion from a standard liquid meal test in subjects with
type 2 diabetes, impaired or normal fasting glucose. Nutr J. 2009;8:22.
27. Carvajal R, Wadden TA, Tsai AG, Peck K, Moran CH. Managing obesity in
primary care practice: a narrative review. Ann N Y Acad Sci. 2013;1281:191–206.
28. Franz MJ, Van Wormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, et al.
Weight-loss outcomes: a systematic review and meta-analysis of weight-loss
clinical trials with a minimum 1-year follow-up. J Am Diet Assoc.
2007;107(10):1755–67. Review.
29. Siri-Tarino PW, Williams PT, Fernstrom HS, Rawlings RS, Krauss RM. Reversal
of small, dense LDL subclass phenotype by normalization of adiposity.
Obesity. 2009;17(9):1768–75.
30. Kerksick CM, Wismann-Bunn J, Fogt D, Thomas AR, Taylor L, Campbell B,
et al. Changes in weight loss, body composition and cardiovascular disease
risk after altering macronutrient distributions during a regular exercise
program in obese women. Nutr J. 2010;9:59.
31. Wijnands MV, Appel MJ, Hollanders VM, Woutersen RA. A comparison of the
effects of dietary cellulose and fermentable galacto-oligosaccharide, in a rat
model of colorectal carcinogenesis: fermentable fibre confers greater
protection than non-fermentable fibre in both high and low fat
backgrounds. Carcinogenesis. 1999;20(4):651–6.
32. Tremaroli V, Backhed F. Functional interactions between the gut microbiota
and host metabolism. Nature. 2012;489:242–9.
33. Freeland KR, Wilson C, Wolever T. Adaptation of colonic fermentation and
glucagon-like peptide-1 secretion with increased wheat fibre intake for 1
year in hyperinsulinaemic human subjects. Br J Nutr. 2010;103:82–90.
Guess et al. Nutrition & Metabolism  (2015) 12:36 Page 9 of 10
34. Williams PG, Grafenauer SJ, O’Shea JE. Cereal grains, legumes, and weight
management: a comprehensive review of the scientific evidence. Nutr Rev.
2008;66(4):171–82.
35. Lê KA, Faeh D, Stettler R, Ith M, Kreis R, Vermathen P, et al. A 4-wk high-
fructose diet alters lipid metabolism without affecting insulin sensitivity or
ectopic lipids in healthy humans. Am J Clin Nutr. 2006;84(6):1374–9.
36. Thomas EL, Brynes AE, Hamilton G, Patel N, Spong A, Goldin RD, et al. Effect
of nutritional counselling on hepatic, muscle and adipose tissue fat content
and distribution in non-alcoholic fatty liver disease. World J Gastroenterol.
2006;28;12(36):5813–9.
37. Chambers ES, Viardot a, Psichas A, Morrison D, Murphy K, Zac-Varghese S
et al. Effects of Elevating Colonic Propionate on Liver Fat Content in Adults
with Non-Alcoholic Fatty Liver Disease. FASEB J. 2015;29(1):no.385.2.
38. Misra A, Sinha S, Kumar M, Jagannathan NR, Pandey RM. Proton magnetic
resonance spectroscopy study of soleus muscle in non-obese healthy and
Type 2 diabetic Asian Northern Indian males: high intramyocellular lipid
content correlates with excess body fat and abdominal obesity. Diabet
Med. 2003;20:361–7.
39. Ng JM, Bertoldo A, Minhas DS, Helbling NL, Coen PM, Price JC, et al.
Dynamic PET imaging reveals heterogeneity of skeletal muscle insulin
resistance. J Clin Endocrinol Metab. 2014;99(1):E102–6.
40. Islam A, Civitarese AE, Hesslink RL, Gallaher DD. Viscous dietary fiber reduces
adiposity and plasma leptin and increases muscle expression of fat
oxidation genes in rats. Obesity. 2012;20:349–55.
41. Stevenson EJ, Astbury NM, Simpson EJ, Taylor MA, Macdonald IA. Fat
oxidation during exercise and satiety during recovery are increased
following a low-glycemic index breakfast in sedentary women. J Nutr.
2009;139:890–7.
42. Weitkunat K, Schumann S, Petzke KJ, Blaut M, Loh G, Klaus S. Effects of
dietary inulin on bacterial growth, short-chain fatty acid production and
hepatic lipid metabolism in gnotobiotic mice. Nutr Biochem.
2015;26(9):929–37.
43. Thorburn A, Muir J, Proietto J. Carbohydrate fermentation decreases hepatic
glucose output in healthy subjects. Metabolism. 1993;42:780–5.
44. Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and
impaired fasting glycaemia: the current status on definition and
intervention. Diabet Med. 2002;19:708–23.
45. Whincup PH, Donin AS. Cereal fibre and type 2 diabetes: time now for
randomised controlled trials? Diabetologia. 2015;58(7):1383–5.
46. Delzenne NM, Cani PD. A place for dietary fibre in the management
of the metabolic syndrome. Curr Opin Clin Nutr Metab Care.
2005;8(6):636–40. Review.
47. Machann J, Thamer C, Schnoedt B, Stefan N, Stumvoll M, Haring HU, et al.
Age and gender related effects on adipose tissue compartments of subjects
with increased risk for type 2 diabetes: a whole body. MRI/MRS study.
MAGMA. 2005;18(3):128–37.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Guess et al. Nutrition & Metabolism  (2015) 12:36 Page 10 of 10
